Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial.
Russell, N Hills, R Kell, J Cavanagh, J Kjeldsen, L McMullin, M Cahalin, P Dennis, Michael Friis, L Grech, A
Russell, N
Hills, R
Kell, J
Cavanagh, J
Kjeldsen, L
McMullin, M
Cahalin, P
Dennis, Michael
Friis, L
Grech, A
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trials. 2016, 173:9-9 Br J Haematol